Xcovery Holdings, Inc. clinical trials
Acquired by Betta Pharmaceuticals Co., Ltd., May 31, 2017 · source ↗
The registry lists 5 studies whose lead sponsor is Xcovery Holdings, Inc.. 2 are recruiting or about to start. Per ClinicalTrials.gov, last updated Apr 30, 2026.
Before and after it joined Betta Pharmaceuticals Co., Ltd.
- First submitted before Xcovery Holdings, Inc. became part of Betta Pharmaceuticals Co., Ltd.
- 2
- First submitted after Xcovery Holdings, Inc. became part of Betta Pharmaceuticals Co., Ltd.
- 3
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
Registry sponsor names on this page
- Xcovery Holdings, Inc.5 studies
Something wrong with this grouping? Tell us on the Betta Pharmaceuticals Co., Ltd. page.
Studies
Recruiting first, then most recently updated. Showing 5 of 5. All Betta Pharmaceuticals Co., Ltd. studies →
- BPI-361175 Tablets in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)Not yet recruitingNCT05393466Phase 1/2
Sponsor listed in the registry: Xcovery Holdings, Inc. · First submitted after Xcovery Holdings, Inc. became part of Betta Pharmaceuticals Co., Ltd.
- Expanded Access to Ensartinib for Participants With ALK+ NSCLCAvailableNCT04146571
Sponsor listed in the registry: Xcovery Holdings, Inc. · First submitted after Xcovery Holdings, Inc. became part of Betta Pharmaceuticals Co., Ltd.
- Phase 1/2 Study of X-396, an Oral ALK Inhibitor, in Patients With ALK-positive Non-Small Cell Lung CancerCompletedNCT01625234Phase 1/2
Sponsor listed in the registry: Xcovery Holdings, Inc. · First submitted before Xcovery Holdings, Inc. became part of Betta Pharmaceuticals Co., Ltd.
- eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) PatientsActive, not recruitingNCT02767804Phase 3
Sponsor listed in the registry: Xcovery Holdings, Inc. · First submitted before Xcovery Holdings, Inc. became part of Betta Pharmaceuticals Co., Ltd.
- A Single Dose BE Study of X-396 in Healthy Volunteers Under Fasted ConditionsCompletedNCT05665283Phase 1
Sponsor listed in the registry: Xcovery Holdings, Inc. · First submitted after Xcovery Holdings, Inc. became part of Betta Pharmaceuticals Co., Ltd.